PLIVA OPENS NEW STATE-OF-THE-ART AZITHROMYCIN PRODUCTION FACILITY
PLIVA, the largest pharmaceutical company in Central and Eastern Europe, announces that its new Azithromycin production plant has been completed. The project worth US$ 100 million is PLIVAs biggest investment in a production site to date. A major part of the investment has been financed by PLIVAs own funds.
Zagreb, 4th September 1998